奥希替尼一线治疗EGFR突变晚期非小细胞肺癌患者的疗效分析  

Efficacy of First-Line Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

作　　者：王千毓 李祥梦 杨衿记 WANG Qian-yu;LI Xiang-meng;YANG Jin-ji(Guangdong Cardiovascular Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangdong Lung Cancer Institute,Guangzhou 510080,China)

机构地区：[1]广东省心血管病研究所,广东省人民医院,广东省医学科学院,广东省肺癌研究所,广州510080

出　　处：《循证医学》2021年第3期178-183,共6页The Journal of Evidence-Based Medicine

基　　金：国家自然科学基金资助项目(81972164)。

摘　　要：目的探讨奥希替尼在临床实践中一线治疗晚期表皮生长因子受体(epidermal growth factor receptor,EGFR)突变非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法回顾性分析2017年6月至2020年1月在广东省人民医院确诊晚期NSCLC且一线使用奥希替尼治疗的患者35例,根据实体瘤疗效评价标准1.1评价近期疗效,通过无进展生存期(progression-free disease,PFS)评价奥希替尼一线治疗EGFR阳性患者的远期疗效。结果在35例患者的最佳疗效中,22例达到部分缓解,5例达到疾病稳定,6例疾病进展。客观缓解率为63%(22/35),疾病控制率为77%(27/35)。中位PFS为14.2个月(95%可信区间10.2~18.3个月)。结论在临床实践中奥希替尼一线治疗晚期EGFR突变晚期NSCLC患者具有明确的疗效。Objective To investigate the clinical efficacy of first-line osimertinib in the treatment of advanced epidermal growth factor receptor(EGFR)-mutated non-small cell lung cancer(NSCLC)patients.Methods Thirty-five EGFR-mutated patients with advanced NSCLC diagnosed in the Guangdong Provincial People's Hospital from June 2017 to January 2020 were retrospectively analyzed.The objective response was evaluated according to Response Evaluation Criteria in Solid Tumors(RECIST)1.1,and the progression-free survival(PFS)was also calculated.Results Among the 35 patients,22 achieved partial response,5 with stable disease,and 6 with progressive disease.The objective response rate was 63%(22/35),and the disease control rate was 77%(27/35).The median PFS was 14.2 months(95% confidence interval,10.2~18.3 months).Conclusions First-line osimertinib was effective in advancedEGFR-mutated NSCLC patients in clinical practice.

关 键 词：奥希替尼 EGFR 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]